Table 1.
Recently initiated clinical trials testing naked DNA-based vaccines in cancer patients*.
| Vaccine | TAA(s) | Co-encoded molecules | Indication | Phase | Status | Estimated enrollment | Delivery | Co-therapy | Ref |
|---|---|---|---|---|---|---|---|---|---|
| GX-188E | E6/E7 | FLT3L | CIN | I | Active, not recruiting | 6 | Intramuscular (electroporation) | None | NCT02100085 |
| CIN | I | Recruiting | 50 | Intramuscular (electroporation) | None | NCT03206138 | |||
| CIN | II | Active, not recruiting | 67 | Intramuscular (electroporation) | None | NCT02411019 | |||
| CIN | II | Active, not recruiting | 134 | Intramuscular (electroporation) | None | NCT02596243 | |||
| INO-1400 | TERT | None | Solid tumors | I | Recruiting | 54 | Intramuscular (electroporation) | INO-9012 | NCT02960594 |
| INO-3112 | E6/E7 | None | Head and neck cancer | Ib/IIa | Not yet recruiting | 50 | Intramuscular (electroporation) | INO-9012 and durvalumab | NCT03162224 |
| Cervical carcinoma | II | Withdrawn | 0 | Intramuscular (electroporation) | INO-9012 and cisplatin | NCT02501278 | |||
| — | Tumor neoantigens | None | TNBC | I | Not yet recruiting | 24 | Intramuscular (electroporation) | Durvalumab | NCT03199040 |
| — | Idiotype | PVXCP or CCL20 | B-cell lymphoma | I | Recruiting | 30 | Intramuscular (PEI) | None | ISRCTN31090206 |
| — | MSLN and tumor neoantigens | None | Pancreatic cancer | I | Not yet recruiting | 15 | Intramuscular (electroporation) | None | NCT03122106 |
Abbreviations: CIN, cervical intraepithelial neoplasia; PEI, polyethylenimine; TAA; tumor-associated antigen, TNBC, triple-negative breast cancer.
*
Initiated between 2015, May 1st and 2017, October 1st